Burjeel Specialty Hospital, Sharjah provides Castleman Disease Treatment using contemporary haematology and immunotherapy approaches, along with evidence-based care. Founded in 2019, the JCI accredited hospital is based in Sharjah, United Arab Emirates, with 75 beds and services for domestic and international patients.

The treatment approach depends on the subtype and severity of the disease. For unicentric Castleman disease, complete surgical removal may be sufficient in many cases. Multicentric disease may require systemic therapy, including medicines that target inflammatory pathways, corticosteroids, or other treatments based on the underlying cause and clinical presentation.